A detailed history of Invesco Ltd. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 182,440 shares of RCUS stock, worth $2.87 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
182,440
Previous 190,683 4.32%
Holding current value
$2.87 Million
Previous $3.6 Million 22.83%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$14.59 - $18.48 $120,265 - $152,330
-8,243 Reduced 4.32%
182,440 $2.78 Million
Q1 2024

May 14, 2024

SELL
$14.83 - $20.18 $28,874 - $39,290
-1,947 Reduced 1.01%
190,683 $3.6 Million
Q4 2023

Feb 12, 2024

SELL
$13.43 - $19.63 $539,536 - $788,615
-40,174 Reduced 17.26%
192,630 $3.68 Million
Q3 2023

Nov 13, 2023

SELL
$17.62 - $23.54 $288,280 - $385,137
-16,361 Reduced 6.57%
232,804 $4.18 Million
Q2 2023

Aug 11, 2023

SELL
$16.97 - $22.03 $576,199 - $748,006
-33,954 Reduced 11.99%
249,165 $5.06 Million
Q1 2023

May 12, 2023

BUY
$15.96 - $23.15 $173,022 - $250,969
10,841 Added 3.98%
283,119 $5.16 Million
Q4 2022

Feb 13, 2023

BUY
$19.7 - $35.71 $113,550 - $205,832
5,764 Added 2.16%
272,278 $5.63 Million
Q3 2022

Nov 14, 2022

SELL
$23.23 - $30.07 $1.72 Million - $2.23 Million
-74,250 Reduced 21.79%
266,514 $6.97 Million
Q2 2022

Aug 15, 2022

BUY
$17.23 - $37.73 $814,806 - $1.78 Million
47,290 Added 16.11%
340,764 $8.64 Million
Q1 2022

May 16, 2022

BUY
$28.92 - $41.83 $2.74 Million - $3.97 Million
94,844 Added 47.75%
293,474 $9.26 Million
Q4 2021

Feb 14, 2022

SELL
$31.38 - $48.47 $817,574 - $1.26 Million
-26,054 Reduced 11.6%
198,630 $8.04 Million
Q3 2021

Nov 15, 2021

BUY
$26.93 - $37.68 $170,493 - $238,552
6,331 Added 2.9%
224,684 $7.83 Million
Q2 2021

Aug 17, 2021

SELL
$22.75 - $35.77 $1.81 Million - $2.84 Million
-79,524 Reduced 26.7%
218,353 $6 Million
Q1 2021

May 17, 2021

SELL
$26.16 - $41.39 $180,006 - $284,804
-6,881 Reduced 2.26%
297,877 $8.36 Million
Q4 2020

Feb 16, 2021

BUY
$17.0 - $32.36 $314,364 - $598,401
18,492 Added 6.46%
304,758 $7.91 Million
Q3 2020

Nov 16, 2020

SELL
$17.14 - $25.47 $88,785 - $131,934
-5,180 Reduced 1.78%
286,266 $4.91 Million
Q2 2020

Aug 14, 2020

BUY
$13.97 - $36.56 $72,015 - $188,466
5,155 Added 1.8%
291,446 $7.21 Million
Q1 2020

May 15, 2020

BUY
$8.78 - $19.28 $2.51 Million - $5.52 Million
286,291 New
286,291 $3.97 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.14B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.